The media spotlight is often a double-edged sword. No one knows this better than people who suffer from Wright Hip Implant adverse events. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.
The media spotlight is often a double-edged sword. No one knows this better than people who suffer from Wright Hip Implant adverse events. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.
Pharmaceutical manufacturer Abbott Laboratories Inc. was sentenced by U.S. District Court Judge Samuel G. Wilson of the Western District of Virginia in connection with its guilty plea related to its unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration (FDA) the Justice Department announced today.
Attorney General Jack Conway today announced that he has recovered another $2.29 million on behalf of the Kentucky Medicaid program following a settlement with Aventis Pharmaceuticals, Inc. and Aventis Behring, LLC, also known as ZLB Behring, Inc. Both drug companies are now owned by Sanofi-Aventis U.S. LLC. This is the latest in a number of settlements in so-called Average Wholesale Price (AWP) lawsuits filed by the Office of the Attorney General against 47 of the nation's largest pharmaceutical companies.
According to court documents, on May 15th 2012, a Massachusetts woman, Janel Mahon, filed a lawsuit in Illinois Southern District Court (case no. 3:2012cv10881) alleging she suffered blood clots leading to a pulmonary embolism from Yaz. Yasmin, which was approved by the FDA in 2001, and its sister drug Yaz, which was approved in 2006, are oral contraceptives that combine estrogen and a fourth generation progestin, drospirenone, to prevent pregnancy. Yaz and Yasmin are manufactured by Bayer Healthcare Pharmaceuticals.
From Associated Press (July 8, 2010)
NEW YORK -- Alcon Inc.’s Independent Director Committee said Thursday it created a litigation trust with $50 million for litigation related to any deal between Alcon and a majority shareholder, with a focus on Novartis.
The trust was formed to provide funds to commence, defend or maintain a lawsuit. Novartis currently owns about 23 percent of Alcon and is trying to buy the company. It has offered up to $39 billion for Alcon.